Technical Analysis for AVCT - Avacta Group Plc
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
24.62 | 7.04% | 1.62 |
AVCT closed up 12.2 percent on Monday, April 6, 2020, on 16.45 times normal volume. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline. It ran into resistance at its 50 day moving average. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
Earnings due: Apr 21
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Up |
| Historical AVCT trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 7.04% | |
| 20 DMA Support | Bullish | 7.04% | |
| Crossed Above 200 DMA | Bullish | 7.04% | |
| Pocket Pivot | Bullish Swing Setup | 7.04% | |
| Volume Surge | Other | 7.04% | |
| Stochastic Reached Overbought | Strength | 7.04% | |
| Multiple of Ten Bullish | Other | 7.04% | |
| Outside Day | Range Expansion | 7.04% | |
| Wide Bands | Range Expansion | 7.04% | |
| Overbought Stochastic | Strength | 7.04% |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Sector: Healthcare
- Industry: Medical Devices
Avacta Group plc is a biotechnology company. Avacta's focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology has been designed to address performance limitations of antibodies. Affimer technology is based on a small protein that can be generated to bind with specificity and affinity to a range of targets to enable diagnostics, research assays and therapeutics. Avacta has a pre-clinical therapeutic development programme with an in-house focus on immuno-oncology and bleeding disorders as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
Biotechnology Medicine Branches Of Biology Medical Specialties Immune System Immunology Antibodies
Biotechnology Medicine Branches Of Biology Medical Specialties Immune System Immunology Antibodies
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 38.4 |
| 52 Week Low | 12.6172 |
| Average Volume | 2,686,793 |
| 200-Day Moving Average | 21.34 |
| 50-Day Moving Average | 23.19 |
| 20-Day Moving Average | 19.46 |
| 10-Day Moving Average | 20.96 |
| Average True Range | 2.47 |
| ADX | 15.0 |
| +DI | 29.09 |
| -DI | 22.91 |
| Chandelier Exit (Long, 3 ATRs ) | 17.49 |
| Chandelier Exit (Short, 3 ATRs ) | 20.03 |
| Upper Bollinger Band | 24.93 |
| Lower Bollinger Band | 13.99 |
| Percent B (%b) | 0.82 |
| BandWidth | 56.21 |
| MACD Line | -0.18 |
| MACD Signal Line | -0.77 |
| MACD Histogram | 0.5813 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 29.63 | ||||
| Resistance 3 (R3) | 29.03 | 26.23 | 28.53 | ||
| Resistance 2 (R2) | 26.23 | 24.54 | 26.53 | 28.16 | |
| Resistance 1 (R1) | 24.61 | 23.50 | 25.42 | 25.21 | 27.79 |
| Pivot Point | 21.81 | 21.81 | 22.21 | 22.11 | 21.81 |
| Support 1 (S1) | 20.19 | 20.12 | 21.00 | 20.79 | 18.21 |
| Support 2 (S2) | 17.39 | 19.08 | 17.69 | 17.84 | |
| Support 3 (S3) | 15.77 | 17.39 | 17.48 | ||
| Support 4 (S4) | 16.37 |
